¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022 ´ëÇѽɺÎÀüÇÐȸ Ãß°è Çмú´ëȸ 3ÀÏÂ÷ : 2022-09-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022 ´ëÇѽɺÎÀüÇÐȸ Ãß°è Çмú´ëȸ 3ÀÏÂ÷ : 2022-09-17
±³À°ÀÏÀÚ : 2022-09-17
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : [¿Â/¿ÀÇÁ¶óÀÎ º´Çà] 2022 ´ëÇѽɺÎÀüÇÐȸ Ãß°è Çмú´ëȸ 3ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ  
´ã´çÀÚ : °­°æ·¡
¿¬¶ôó : 02-3275-5335  
À̸ÞÀÏ : khfs3@khfs.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 55ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í ±³¼ö: 70,000¿øÀüÀÓÀÇ,Á¦¾à °ü·Ã Á¾»çÀÚ: 30,000¿ø Àü°øÀÇ, °£È£»ç, ±âŸ(ÀÌ¿Ü ÀÇ·áÁ¾»çÀÚ), ±ºÀÇ°ü: 10,000¿ø65¼¼ ÀÌ»ó, Çлý, ±âŸ(ÀÌ¿Ü ÀÇ·áÁ¾»çÀÚ): ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 09:00~09:15 Current status of heart transplantation in Korea with challenging case  ±è°æÈñ(ÀÎõ¼¼Á¾º´¿ø) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 09:15~09:35 2022 Update on heart transplant with case discussion  Andreas Zuckermann(Medical University of Vienna, Austria) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 09:35~09:50 Antibody mediated rejection, what is new?  ÃÖÈ¿ÀÎ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 09:50~10:05 Non-invasive monitoring of rejection after heart transplantation  Josef Stehlik(University of Utah, USA) 
Åä·Ð 09-17 ±×·£µåº¼·ë 10:05~10:30 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-17 ±×·£µåº¼·ë 10:30~11:00 Coffee Break  () 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 11:00~11:20 Prevalence and cumulative risk of familial idiopathic  Ray Hershberger(The Ohio State University, USA) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 11:20~11:35 The state of precision cardiovascular medicine status in Korea  ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 11:35~11:50 Genetic basis of myocardial recovery in dilated cardiomyopathy: Potential therapeutic implications  Naveen Pereira(Mayo Clinic, USA) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 11:50~12:05 Contributions of sarcomere and mitochondria-related multigene variants to the endophenotype of Hypertrophic Cardiomyopathy  ÃÖÀÇ¿µ(¿¬¼¼ÀÇ´ë) 
Åä·Ð 09-17 ±×·£µåº¼·ë 12:05~12:30 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
½Ä»ç 09-17 ±×·£µåº¼·ë 12:30~13:30 Lunch  () 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 13:30~13:45 Impella in advanced heart failure: Is revolutionized the field of mechanical circulatory support?  Jun Nakata(Nippon Medical School Hospital, Japan) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 13:45~14:00 Overcome for donor shortage: How to improve donor heart utilization?  ÇöÁØÈ£(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 14:00~14:15 Emergence of destination therapy in Japan  Koichiro Kinugawa(University of Toyama, Japan) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 14:15~14:30 Heart transplantation in patients with mechanical circulatory support : What should be aware of?  À̼ö¿ë(ºÎ»êÀÇ´ë) 
Åä·Ð 09-17 ±×·£µåº¼·ë 14:30~15:00 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-17 ±×·£µåº¼·ë 15:00~15:20 Coffee Break  () 
±âŸ 09-17 ±×·£µåº¼·ë 15:20~15:25 Keynote lecture (Session introduction): °³¿øÀÇÀÇ ÀÔÀå¿¡¼­ ¹Ù¶óº» ½ÉºÎÀü Àü¹®ÀÇ ¿ªÇÒ  ±èÇѼö(ºÐ´ç21¼¼±â³»°ú) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 15:25~15:40 Take 1. Heart failure diagnosis: Diagnosis of heart failure patient - Diagnostic work ( stage A to C)  È²ÀÎâ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 15:40~15:55 Take 2. Chronic heart failure management: Medical treatment - How to implement guideline directed medical treatment  ±èÇüÀ±(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 15:55~16:10 Take 3. Chronic heart failure management: Comorbidities - How to manage important comorbidities in heart failure  ÀÌÁ¤Àº(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-17 ±×·£µåº¼·ë 16:10~16:25 Take 4. Chronic heart failure Management: When to refer?  ¼º¼®¿ì(Ãæ³²ÀÇ´ë) 
Åä·Ð 09-17 ±×·£µåº¼·ë 16:25~16:50 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022 ´ëÇѽɺÎÀüÇÐȸ Ãß°è Çмú´ëȸ 3ÀÏÂ÷ : 2022-09-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022 ´ëÇѹ̿뼺Çü·¹ÀÌÀúÀÇÇÐȸ Ãß°èÇмú´ëȸ : 2022-09-18
´ÙÀ½±Û Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç ¿¬¼ö°­Á : 2022-09-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20835 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ 2024³â Á¦ 1ȸ ³»½Ã°æ Áý´ãȸ : 2024-06-21 0 33 2024-05-27
20834 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ)¾È°ú ±Ý¿äÁý´ãȸ : 2024-06-21 0 9 2024-05-27
20833 ¼­¿ï ´ëÇѳúÀüÁõÇÐȸ 29rd KOREAN EPILEPSY CONGRESS (2024 KEC) 1ÀÏÂ÷ : 2024-06-21 0 26 2024-05-27
20832 ¼­¿ï Á¦8Â÷ µµºÀ±¸ÀÇ»çȸ Çмú¼¼¹Ì³ª(½ÉÇ÷°üÁúȯ ȯÀÚÀÇ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·á, ºÒ¸éÁõ, Ä¡¸Å¾à¹°Ä¡·á, Ç×Ç÷ÀüÁ¦) : 2024-06-21 0 16 2024-05-27
20831 ºÎ»ê 2024³âµµ ºÎ»ê․°æ³²Áö¿ª ÀÇ°ú´ëÇÐ ½ÅÀÓ±³¼ö ¿öÅ©¼ó (2ÀÏÂ÷) : 2024-06-21 0 5 2024-05-27
20830 Á¦ÁÖ ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-06-21 0 9 2024-05-27
20829 ¼­¿ï 2024³â °áÇÙ°ü¸®±³À° 2±â(1ÀÏÂ÷) : 2024-06-20 0 6 2024-05-27
20828 ºÎ»ê ´ëÇѼҾÆû¼Ò³â°úÇÐȸ ºÎ»êÁöȸ Áý´ãȸ : 2024-06-20 0 16 2024-05-27
20827 ºÎ»ê ´ëÇѾȰúÇÐȸ ºÎ»êÁöȸ Á¦ 510ȸ ÇмúÁý´ãȸ : 2024-06-20 0 11 2024-05-27
20826 ºÎ»ê 2024³âµµ ºÎ»ê․°æ³²Áö¿ª ÀÇ°ú´ëÇÐ ½ÅÀÓ±³¼ö ¿öÅ©¼ó (1ÀÏÂ÷) : 2024-06-20 0 8 2024-05-27
20825 ¼­¿ï (¿Â¶óÀÎ) ´ëÇÑÅëÁõÇÐȸ ¼­¿ïÁöȸ Áý´ãȸ : 2024-06-20 0 12 2024-05-27
20824 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À°(¼­½Ä ÀÛ¼º ½ÇÁ¦) : 2024-06-20 0 8 2024-05-27
20823 °æ±â µ¿±¹´ëÇб³ Àϻ꺴¿ø : °ñ°üÀý¿°ÀÇ Áø´Ü ¹× Ä¡·á : 2024-06-19 0 10 2024-05-27
20822 °æ±â ´ëÇÑ°£ÇÐȸ Overlooked Liver Diseases : 2024-06-19 0 19 2024-05-27
20821 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ Á¦2ȸ ÃÊÀ½ÆÄ ½ÇÀü ¾ÆÄ«µ¥¹Ì : 2024-06-17 0 30 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷